Welcome to our dedicated page for INSULET SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INSULET's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INSULET's regulatory disclosures and financial reporting.
Insulet Corp (PODD) amended its existing credit agreement, refinancing $475 million of outstanding term loans with an equal amount of new term loans that carry lower interest margins. The new loans have interest rate margins of 0.75% for base rate loans and 1.75% for term SOFR loans, with a 0.00% SOFR floor, representing a 0.25% reduction in margin compared with the prior term loans. The new term loans were issued at par, and, together with cash on hand, were used to repay the existing term loans and accrued interest.
The amendment also increases Insulet’s revolving credit commitments by $250 million to a total of $750 million, which were undrawn on the closing date. The margin range on SOFR-based revolving loans is reduced from 1.50%–2.00% to 1.25%–1.75%, with the actual margin tied to the company’s adjusted total leverage ratio. Borrowings and letters of credit under this revolving facility may be used for working capital and other general corporate purposes of Insulet and its subsidiaries.
INSULET CORP (PODD) reported that its Talent and Compensation Committee approved and adopted the Insulet Nonqualified Deferred Compensation Plan, effective January 1, 2027. The plan is an unfunded "top hat" deferred compensation arrangement for a select group of management or highly compensated employees, including named executive officers, designed to comply with Section 409A of the Internal Revenue Code and ERISA requirements.
Eligible participants designated by the committee may elect to defer up to 60% of cash compensation, including base salary and annual incentive bonus, with all participant deferrals and related earnings fully vested. The plan allows, but does not require, the company to make matching, nonelective, and discretionary contributions that generally follow a two-year cliff vesting schedule and vest fully upon a change in control. Deferred amounts are paid in cash as a lump sum or installments after a specified date or upon separation from service, death, or disability, with payments beginning on the first payroll date of the seventh month after separation and all accounts paid within 30 days following a change in control. The committee may amend or terminate the plan, provided existing earned benefits are not reduced.
Insulet Corporation (PODD) announced two upcoming changes to its Board of Directors. On September 3, 2026, longtime director Timothy J. Scannell informed the company he would step down from the Board for health reasons, effective the same day, after 12 years of service, including 7 years as Chairman of the Board.
On September 8, 2026, director Michael R. Minogue notified the company of his decision to step down from the Board, effective September 15, 2026, to focus on his candidacy for Governor of Massachusetts, after 9 years of service. The company states that neither director resigned due to any disagreement with the company on operations, policies, or practices.
INSULET CORP (PODD) director and President and CEO Ashley McEvoy reported an open-market purchase of 1,100 shares of common stock on 2026-08-21 at a weighted average price of $147.47 per share, with individual trade prices ranging from $147.42 to $147.62. After this transaction, McEvoy directly holds 23,731 shares of Insulet common stock, which include 80 shares acquired through the Insulet Corporation Employee Stock Purchase Plan since the prior Form 4 filing, and also reports 4 shares held indirectly by a trust.
FMR LLC and Abigail P. Johnson report updated ownership in Insulet Corp common stock on a Schedule 13G/A. FMR LLC is shown as beneficially owning 964,296.97 shares, representing 1.4% of the class. FMR LLC has sole voting power over 692,986.46 shares and sole dispositive power over 964,296.97 shares, with no shared voting or dispositive power. The filing notes that one or more other persons have rights to dividends or sale proceeds in these shares, but no single such person holds more than five percent of Insulet’s outstanding common stock.
Insulet Corporation reported strong results for the three months ended June 30, 2026. Revenue reached $801.7 million, up 23.5% (22.7% in constant currency), led by Omnipod revenue of $795.9 million. U.S. Omnipod grew 20.1% to $544.1 million, while International Omnipod rose 35.5% to $251.8 million. Operating income was $129.7 million, or 16.2% of revenue, and adjusted operating income was $154.5 million, or 19.3% of revenue. Net income increased to $95.0 million, or $1.37 per diluted share, and adjusted diluted EPS was $1.66.
For the six months ended June 30, 2026, revenue was $1,563.4 million and free cash flow was $145.4 million. For full‑year 2026, Insulet now expects constant‑currency revenue growth of 20%–22%, compared with prior guidance of 21%–23%, and continues to target about 100 basis points of adjusted operating margin expansion. The outlook for adjusted EPS growth is now >30%, compared with >25% in prior guidance. Third‑quarter 2026 constant‑currency revenue growth is projected at 18%–20% for Total Omnipod and 17.5%–19.5% for the Company overall.
Strategically, Insulet expanded Omnipod 5 and Omnipod into Spain, enhanced the Omnipod 5 algorithm and sensor compatibility, presented new clinical data on Omnipod 6 and a fully closed‑loop technology for people with type 2 diabetes, and partnered with Calm to provide mindfulness, sleep and stress‑management tools for the diabetes community.
Insulet Corp executive Lisa Blair Davis, SVP and Chief HR Officer, reported a tax-withholding disposition of 244 shares of common stock on 2026-08-01 at $165.35 per share to cover RSU-related tax obligations. After this withholding, she directly holds 4,453 shares, including 80 shares acquired through the Employee Stock Purchase Plan.
Insulet Corp director Robert Luther Huffines reported an amended grant of 151 deferred common stock units received in lieu of cash fees under the company’s Deferred Compensation Plan for Non-Employee Directors. These Deferred Units convert into common stock on a one-for-one basis upon distribution.
The amendment corrects an administrative error in the original Form 4, revising the award to 151 units at a price of $152.25 per unit, instead of 144 units at $159.79. Following this adjustment, Huffines holds 2,449 shares directly.
INSULET CORP director Jonathan Jay Mazelsky received an initial equity award in the form of restricted stock units, which convert into common shares on a one-for-one basis. The award covers 1,355 shares of common stock at a stated price of $0.00 per share, reflecting a compensation grant rather than an open-market purchase.
After this grant, Mazelsky directly holds 1,355 shares of Insulet common stock according to the filing. The transaction is categorized as a grant, award, or other acquisition of non-derivative common stock, tied to his role on the company’s board.